Tidepath

GLP-1 and glucagon drugs

Mazdutide

Also called IBI362, LY3305677

A weekly shot acting on GLP-1 and glucagon, approved in China15.

Status
Approved in China in 2025, for weight management and for type 2 diabetes; not approved by the FDA1210.
How it's taken
By injection

What it is

Mazdutide acts on two receptors: GLP-1 and glucagon5. GLP-1 is a hormone your gut releases when you eat11, and glucagon is a hormone that raises blood sugar. It's modelled on oxyntomodulin, a gut hormone that acts on both of those receptors34. In research on oxyntomodulin, the GLP-1 side lowers how much is eaten, and the glucagon side raises how much energy the body burns4. Mazdutide carries a fatty acid chain that makes it last longer in the body, so it can be injected under the skin once a week347.

What makes it distinct

Mazdutide is approved in China, for weight management and for type 2 diabetes12. Innovent holds the rights there under a license from Eli Lilly, which has tested it in a phase 2 trial in the US19.

What the evidence shows

In GLORY-1, a phase 3 trial in China, 610 adults with obesity, or overweight and a related health problem, took weekly mazdutide or a placebo for 48 weeks5. People on mazdutide lost more weight than people on placebo, and measures of heart and metabolic health improved too5. GLORY-2 tested a higher dose for 60 weeks in 461 Chinese adults with obesity, with the same kind of result6. In DREAMS-1, 320 Chinese adults with type 2 diabetes that diet and exercise alone weren't controlling saw their HbA1c, a blood test of average blood sugar, fall more on mazdutide than on placebo7. In the US, a phase 2 trial funded by Eli Lilly gave 179 adults with obesity or overweight and no type 2 diabetes mazdutide or a placebo for 48 weeks, and people on mazdutide lost more weight than people on placebo9. Stomach and gut side effects were the most common, mostly mild to moderate59. In GLORY-2, vomiting, nausea and diarrhea were the most common side effects, and most side effects were mild to moderate6.

Open questions

  • How results in Chinese adults apply to other groups. Its phase 3 trials enrolled adults in China, and the US trial was a smaller phase 2569.
  • Effects over longer periods. The trials here ran up to 60 weeks6.

Sources

  1. Innovent press release, 27 June 2025: Mazdutide received approval from China's NMPA for chronic weight management (PR Newswire)
  2. Innovent press release, 19 September 2025: Mazdutide received approval from China's NMPA for glycemic control in adults with type 2 diabetes (PR Newswire)
  3. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun 2023 (full text)
  4. A phase 1b randomised controlled trial of a GLP-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun 2022 (full text)
  5. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). N Engl J Med 2025
  6. Treatment With Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA 2026 (PubMed 42251595)
  7. Mazdutide versus placebo in Chinese adults with type 2 diabetes (DREAMS-1). Nature 2026
  8. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2026
  9. FDA: Novel Drug Approvals for 2026 (content current as of 10/20/2026)
  10. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)

More in GLP-1 and glucagon drugs